PRESENTATION TITLE

Targeting Mesothelioma

PRESENTER(S)

Aaron S. Mansfield, M.D., Consultant and Professor of Medical Oncology, Mayo Clinic, Rochester, Minnesota

PRESENTER BIO

Aaron Mansfield, M.D., is a medical oncologist with a focus on translational research in thoracic malignancies and early cancer therapeutics. His work has supported the FDA-approval of novel frontline therapies for small cell lung cancer (atezolizumab) and mesothelioma (ipilimumab and nivolumab); a MET inhibitor for non-small cell lung cancer (capmatinib) and a RET inhibitor for non-small cell lung cancer and thyroid cancers (pralsetinib). His research has focused on genomic predictors of survival with immunotherapy and is supported by an NCI R21 award, a DoD award and a Mark Foundation ASPIRE award.

VIEWING LOCATIONS
Zoom Registration Link

LEARNING OBJECTIVES

• Recall the etiologies of mesothelioma.
• Assess therapeutic approaches for mesothelioma.
• Identify patterns of genomic abnormalities in mesothelioma.
• Assess the predictive significance of tumor junction burden.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.